DSIP vs Vesugen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- Half-Life
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, IV, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100–400 mcg
- 10 mg per day
- Frequency
- Once nightly
- Daily for 10–30 days
- Key Benefits
- Induces and deepens delta-wave (slow-wave) sleep
- Reduces cortisol and normalizes HPA axis
- Improves sleep quality in insomnia patients
- Anti-stress and anxiolytic effects
- May improve opiate/alcohol withdrawal symptoms
- Analgesic properties through opioid modulation
- Antioxidant and neuroprotective effects
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Side Effects
- Generally well tolerated
- Mild grogginess next morning at higher doses
- Rare: hypotension
- Potential for altered dream patterns
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Stacks With
- —
- —